Tanios Bekaii-Saab, MD, FACP, discusses the evolving treatment paradigm for BRCA1- and BRCA2-positive pancreatic cancer in the first-line setting. Tanios Bekaii-Saab, MD, FACP, professor, medicine, Mayo Clinic College of Medicine and Science; leader, Gastrointestinal Cancer Program, Mayo Clinic Comprehensive Cancer Center; medical director, Cancer Clinical Research Office; vice chair, section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the evolving treatment paradigm for patients with BRCA1- and BRCA2-positive pancreatic cancer in the first-line setting.